Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GED-0301 maintenance extension study in Crohn's disease remission
2011-005678-47Phase 2Terminated
- Sponsor
- Giuliani
- Start
- Dec 2011
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of mongersen in Crohn's disease, sponsored by Giuliani. Started Dec 2011; status: terminated.
02
Drugs
mongersen
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2011-005678-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005678-47.